Clinical trialNCT06961214RecruitingPhase 3Interventional

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

SponsorGlaxoSmithKlineEnrollment960Pulmonary Disease, Chronic Obstructive

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

GSK Clinical Trials
GlaxoSmithKline
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

159 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Buenos Aires, Argentina
Nicolas Itcovici
Recruiting
Gsk Investigational Site
Buenos Aires, Argentina
Pablo Doreski
Recruiting
Gsk Investigational Site
Córdoba, Argentina
Fernando Bordese
Recruiting
Gsk Investigational Site
Quilmes, Argentina
Julian Mereles
Recruiting
Gsk Investigational Site
Santa Fe, Argentina
Martin Maillo
Recruiting

Australia

Gsk Investigational Site
Coffs Harbour, New South Wales, Australia
Olga Voloshyna
Recruiting
Gsk Investigational Site
Maroubra, New South Wales, Australia
Mark Arya
Recruiting
Gsk Investigational Site
Westmead, New South Wales, Australia
Stephen Milne
Recruiting
Gsk Investigational Site
Midland, Western Australia, Australia
David Manners
Recruiting

Austria

Gsk Investigational Site
Graz, Austria
Katrin Milger
Recruiting
Gsk Investigational Site
Innsbruck, Austria
Thomas Sonnweber
Recruiting
Gsk Investigational Site
Klagenfurt, Austria
Daniel Doberer
Recruiting
Gsk Investigational Site
Linz, Austria
Christopher Lambers
Recruiting
Gsk Investigational Site
Linz, Austria
Michael Wuertz
Recruiting
Gsk Investigational Site
Linz, Austria
Andreas Horner
Recruiting
Gsk Investigational Site
Vienna, Austria
Marco Idzko
Recruiting

Bulgaria

Gsk Investigational Site
Dupnitsa, Bulgaria
Elena Gyuzeleva
Recruiting
Gsk Investigational Site
Haskovo, Bulgaria
Veselin Kalfov
Recruiting
Gsk Investigational Site
Lovech, Bulgaria
Mihail Kirov
Recruiting
Gsk Investigational Site
Montana, Bulgaria
Vanko Vankov
Recruiting
Gsk Investigational Site
Montana, Bulgaria
Lidia Nikolcheva
Recruiting
Gsk Investigational Site
Pleven, Bulgaria
Mariya Todorova
Recruiting
Gsk Investigational Site
Rousse, Bulgaria
Nikolay Nikolaev
Recruiting
Gsk Investigational Site
Rousse, Bulgaria
Hristo Metev
Recruiting
Gsk Investigational Site
Sofia, Bulgaria
Kiril Palaveev
Recruiting
Gsk Investigational Site
Sofia, Bulgaria
Georgi Hinkov
Recruiting

Czechia

Gsk Investigational Site
Jindřichův Hradec, Czechia
Petr Kopecký jr
Recruiting
Gsk Investigational Site
Kralupy nad Vltavou, Czechia
Otakar Hokynar
Recruiting
Gsk Investigational Site
Nymburk, Czechia
Sarka Klimesova
Recruiting
Gsk Investigational Site
Prague, Czechia
Zuzana Bouckova
Recruiting
Gsk Investigational Site
Varnsdorf, Czechia
Milan Sklenar
Recruiting

Germany

Gsk Investigational Site
Munich, Bavaria, Germany
Korkut Avsar
Recruiting
Gsk Investigational Site
Offenbach, Hesse, Germany
Florieke Berfelo
Recruiting
Gsk Investigational Site
Rheine, North Rhine-Westphalia, Germany
Marc Hoeffgen
Recruiting
Gsk Investigational Site
Bendorf, Germany
Olaf Schmidt
Recruiting
Gsk Investigational Site
Berlin, Germany
Lennart Schaper
Recruiting
Gsk Investigational Site
Berlin, Germany
Thomas Lienert
Recruiting
Gsk Investigational Site
Berlin, Germany
Bjoern Martens
Recruiting
Gsk Investigational Site
Berlin, Germany
Hilke Temme
Recruiting
Gsk Investigational Site
Berlin, Germany
Thomas Schultz
Recruiting

119 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DepemokimabPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Jun 2025
Primary completion: 21 Aug 2029
Completion: 21 Aug 2029
Last update posted: 9 Apr 2026
Registered enrollment: 960
Registry id: NCT06961214

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-520417-41-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.